MLTX
MoonLake Immunotherapeutics
NASDAQ: MLTX · HEALTHCARE · BIOTECHNOLOGY
$16.38
+1.68% today
Updated 2026-04-30
Market cap
$1.23B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.53
Dividend yield
—
52W range
$6 – $63
Volume
1.1M
MoonLake Immunotherapeutics (MLTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-316692.00 | $-35.18M | $-55.89M | $-42.78M | $-116.59M | $-196.01M |
| Capital expenditures | $0.00 | $50706.00 | $16010.00 | $284634.00 | $519520.00 | $35000.00 |
| Depreciation | — | — | — | — | — | — |
| Stock-based comp | — | $10863.00 | $9654.00 | $7.11M | $7.28M | $12.90M |
| Free cash flow | $-316692.00 | $-35.23M | $-55.91M | $-43.06M | $-117.11M | $-196.04M |
| Investing cash flow | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — |
| Dividends paid | — | $51915.00 | — | — | — | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | $-669134.00 | $31.46M | — | — | — |